Usana Health Sciences (USNA) EV to EBITDA (2010 - 2026)

Usana Health Sciences (USNA) has reported EV to EBITDA for 17 consecutive years, with 13.67 the latest figure, recorded in Q3 2026.

• On a quarterly basis, EV to EBITDA fell 148.44% year-over-year to 13.67 in Q3 2026; TTM through Jul 2026 was 253.24, a 3117.47% decrease from a year earlier, with the FY2026 full-year figure at 6.68, down 19.82% from the prior year.
• EV to EBITDA was 13.67 for Q3 2026 at Usana Health Sciences, down from 14.44 in the prior quarter.
• Over five years, EV to EBITDA peaked at 350.84 in Q3 2025 and troughed at 13.67 in Q3 2026.
• A 5-year average of 49.88 and a median of 34.2 in 2023 frame the typical range for EV to EBITDA.
• Across the five-year window, EV to EBITDA surged 1430.13% in 2025 and tumbled 148.44% in 2026, its largest moves.
• Over 5 years, EV to EBITDA stood at 32.52 in 2022, then decreased by 11.76% to 28.69 in 2023, then soared by 134.68% to 67.34 in 2024, then soared by 421.01% to 350.84 in 2025, then plunged by 103.89% to 13.67 in 2026.
• The last three EV to EBITDA figures came in at 13.67 (Q3 2026), 14.44 (Q2 2026), and 65.51 (Q1 2026), per Business Quant data.